Compare Smith & Nephew plc (SNN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M). The key difference: Smith & Nephew plc is far larger — about 15.9× YieldMax TSLA Option Income Strategy ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| SNN | TSLY | |
|---|---|---|
Market Cap | $11.10B | $697.51M |
Volume | 1,051,703 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $37.17 | $43.35 |
52-Week Low | $26.42 | $20.49 |
Typical Hold Time | 121 Days | 43 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
TSLY trades at $22.27, down 1.46% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF generates high income through weekly dividends, averaging around $0.21-$0.26 per share recently. Recent news highlights consistent distribution announcements but also notes underperformance versus Tesla's equity rally due to its option income strategy structure.
The outlook is mixed: high yield appeals to income seekers, but the strategy caps upside during Tesla rallies. Key risks include dependence on Tesla's volatility and potential NAV erosion. Investors should weigh income generation against limited capital appreciation potential in a bullish Tesla market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
